Eloxatin

Oxaliplatin

In combination w/ 5-fluorouracil (5-FU) & folinic acid as adjuvant treatment of stage III (Dukes C) colon cancer after complete resection of primary tumour; treatment of metastatic colorectal cancer.

IV Always administer before fluoropyrimidines (eg, 5-FU). Administer as a 2- to 6-hr infusion. Adult Adjuvant treatment 85 mg/m² every 2 wk for 12 cycles (6 mth). Metastatic colorectal cancer 85 mg/m² every 2 wk until disease progression or unacceptable toxicity. Patient w/ mild to moderate renal impairment 85 mg/m².

Hypersensitivity. Patients w/ myelosuppression (evidenced by baseline neutrophils <2 x 10⁹/L &/or platelet count <100 x 10⁹/L) &/or peripheral sensitive neuropathy w/ functional impairment prior to 1st course. Patients w/ severe renal impairment (CrCl <30 mL/min). Lactation.

Immediately interrupt infusion & start appropriate symptomatic treatment in case of anaphylactic manifestations. Perform a neurological exam before each administration & periodically thereafter. Possibility of persistent symptoms of peripheral sensory neuropathy after treatment completion. Perform FBC w/ white cell differential prior to start of therapy & each subsequent course. Risk of diarrhoea/emesis, mucositis/stomatitis & neutropenia after oxaliplatin & 5-FU administration; GI ulcer & potential complications eg, GI hemorrhage & perforation. Reports of reversible posterior leukoencephalopathy syndrome; sepsis, neutropenic sepsis & septic shock; rhabdomyolysis. Discontinue in case of unexplained resp symptoms (eg, non-productive cough, dyspnoea, crackles or radiological pulmonary infiltrates) until interstitial lung disease is excluded; microangiopathic haemolytic anaemia, disseminated intravascular coagulation. Patients w/ history of allergic manifestations to other platinum-containing products. Patients w/ history or predisposition for QT prolongation, those taking medicinal products known to prolong QT interval, & those w/ electrolyte disturbances eg, hypokalemia, hypocalcaemia, or hypomagnesaemia. Minor or moderate influence on ability to drive & use machines. Patients w/ mild to moderate renal impairment. May have an anti-fertility effect. Appropriate contraceptive measures must be taken during & after cessation of therapy during 4 mth for women & 6 mth for men. Not recommended during pregnancy & in women of childbearing potential not using contraception.

Infection; anaemia, neutropenia, thrombocytopenia, leukopenia, lymphopenia; allergy/allergic reaction; anorexia, hyperglycaemia, hypokalaemia, hypernatraemia; peripheral sensory neuropathy, sensory disturbance, dysgeusia, headache; dyspnoea, cough, epistaxis; nausea, diarrhoea, vomiting, stomatitis/mucositis, abdominal pain, constipation; skin disorders, alopecia; back pain; fatigue, fever, asthenia, pain, inj site reaction; increased hepatic enzymes, blood alkaline phosphatase, blood bilirubin, blood lactate dehydrogenase, wt (adjuvant setting). Rhinitis, upper resp tract infection, neutropenic sepsis; febrile neutropenia; dehydration, hypocalcaemia; depression, insomnia; dizziness, motor neuritis, meningism; conjunctivitis, visual disturbance; haemorrhage, flushing, DVT, HTN; hiccups, pulmonary embolism; dyspepsia, gastroesophageal reflux, GI &/or rectal haemorrhage; skin exfoliation (eg, hand & foot syndrome), erythematous rash, rash, hyperhidrosis, nail disorder; arthralgia, bone pain; haematuria, dysuria, abnormal micturition frequency; increased blood creatinine, decreased wt (metastatic setting); fall.

Caution when co-administered w/ other medicinal products known to cause QT interval prolongation; other medicinal products known to be associated w/ rhabdomyolysis.

Cytotoxic Chemotherapy

L01XA03 - oxaliplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

P₁S₁S₃